SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer.
Cervical cancer
DNMT3A
Galectin-9
H3K9me3
SUV39H1
Tim-3
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
04
2020
accepted:
24
06
2020
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
24
7
2020
Statut:
epublish
Résumé
Methylation of histone 3 at lysine 9 (H3K9) and DNA methylation are epigenetic marks correlated with genes silencing. The tumor microenvironment significantly influences therapeutic responses and clinical outcomes. The epigenetic-regulation mechanism of the costimulatory factors Tim-3 and galectin-9 in cervical cancer remains unknown. The methylation status of SUV39H1 up-regulates H3K9me3 expression at the These results indicate that SUV39H1-DNMT3A is a crucial Tim-3 and galectin-9 regulatory axis in cervical cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Methylation of histone 3 at lysine 9 (H3K9) and DNA methylation are epigenetic marks correlated with genes silencing. The tumor microenvironment significantly influences therapeutic responses and clinical outcomes. The epigenetic-regulation mechanism of the costimulatory factors Tim-3 and galectin-9 in cervical cancer remains unknown.
METHODS
METHODS
The methylation status of
RESULTS
RESULTS
SUV39H1 up-regulates H3K9me3 expression at the
CONCLUSION
CONCLUSIONS
These results indicate that SUV39H1-DNMT3A is a crucial Tim-3 and galectin-9 regulatory axis in cervical cancer.
Identifiants
pubmed: 32699524
doi: 10.1186/s12935-020-01380-y
pii: 1380
pmc: PMC7370487
doi:
Types de publication
Journal Article
Langues
eng
Pagination
325Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no potential conflicts of interest.
Références
J Immunol. 2008 Aug 15;181(4):2878-86
pubmed: 18684979
Curr Probl Cancer. 2018 Sep;42(5):457-465
pubmed: 30064936
Oncol Rep. 2017 Nov;38(5):2587-2596
pubmed: 29048620
PLoS One. 2015 Dec 23;10(12):e0145700
pubmed: 26697877
Nat Commun. 2019 May 16;10(1):2188
pubmed: 31097695
Cancer Lett. 2020 Apr 28;476:87-96
pubmed: 32061753
Oncol Rep. 2019 Dec;42(6):2655-2669
pubmed: 31661141
Signal Transduct Target Ther. 2019 Dec 13;4:55
pubmed: 31871774
Oncogene. 2017 Oct 5;36(40):5648-5657
pubmed: 28581523
Immunotherapy. 2017 Jan;9(1):99-108
pubmed: 28000527
Int J Mol Sci. 2019 May 15;20(10):
pubmed: 31096567
Nat Rev Mol Cell Biol. 2015 Sep;16(9):519-32
pubmed: 26296162
Oncogene. 2018 May;37(18):2456-2468
pubmed: 29449693
Cancer Immunol Res. 2019 Mar;7(3):414-427
pubmed: 30610059
Elife. 2017 Aug 01;6:
pubmed: 28760201
Endocrinology. 2012 Oct;153(10):4905-17
pubmed: 22865368
Cell Rep. 2016 Nov 15;17(8):2101-2111
pubmed: 27851971
Acta Oncol. 2015 Nov;54(10):1706-13
pubmed: 26361073
Inflammation. 2018 Feb;41(1):1-10
pubmed: 28852907
PLoS One. 2013;8(3):e58006
pubmed: 23526963
Lancet. 2013 Sep 7;382(9895):889-99
pubmed: 23618600
Cleve Clin J Med. 2019 Mar;86(3):173-178
pubmed: 30849035
J Oral Pathol Med. 2018 Jan;47(1):91-95
pubmed: 28976032
Carcinogenesis. 2015 Dec;36(12):1453-63
pubmed: 26449251
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Immunol Immunother. 2016 May;65(5):587-99
pubmed: 27000869
Oncogene. 2015 Jan 2;34(1):104-18
pubmed: 24292684
Tumour Biol. 2017 Mar;39(3):1010428317694573
pubmed: 28351298
Mol Cell Biol. 2005 May;25(10):3923-33
pubmed: 15870267
Lab Invest. 2014 Nov;94(11):1200-11
pubmed: 25264706
Adv Genet. 2010;70:27-56
pubmed: 20920744